Prix FamiCord AG (VTIAF)

FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. The company is headquartered in Leipzig, Sachsen and currently employs 771 full-time employees. The company went IPO on 2007-11-21. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The firm acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.